Gossamer Bio Inc (NASDAQ:GOSS)’s stock price fell 6% during trading on Friday . The stock traded as low as $14.51 and last traded at $14.55, 514,600 shares were traded during mid-day trading. An increase of 19% from the average session volume of 432,477 shares. The stock had previously closed at $15.48.

Several brokerages have recently commented on GOSS. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 target price (down previously from $34.00) on shares of Gossamer Bio in a research note on Tuesday, December 17th. Bank of America began coverage on shares of Gossamer Bio in a research note on Tuesday, December 3rd. They issued a “buy” rating and a $32.00 target price on the stock. Berenberg Bank initiated coverage on shares of Gossamer Bio in a research note on Wednesday, October 30th. They issued a “buy” rating and a $31.00 target price on the stock. BidaskClub upgraded shares of Gossamer Bio from a “sell” rating to a “hold” rating in a research report on Tuesday. Finally, ValuEngine upgraded shares of Gossamer Bio from a “hold” rating to a “buy” rating in a research report on Monday. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Gossamer Bio presently has a consensus rating of “Buy” and an average target price of $27.29.

The company’s 50-day moving average is $14.51 and its 200-day moving average is $18.74. The firm has a market cap of $1.02 billion and a price-to-earnings ratio of -0.64. The company has a debt-to-equity ratio of 0.09, a quick ratio of 13.64 and a current ratio of 13.64.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.10). On average, analysts predict that Gossamer Bio Inc will post -3.05 EPS for the current year.

In related news, insider Jakob Dupont sold 1,994 shares of the company’s stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $15.81, for a total transaction of $31,525.14. Following the transaction, the insider now owns 1,994 shares in the company, valued at approximately $31,525.14. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 23.30% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in GOSS. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Gossamer Bio during the 4th quarter valued at about $45,000. Bank of Montreal Can lifted its position in Gossamer Bio by 29.0% during the 4th quarter. Bank of Montreal Can now owns 5,962 shares of the company’s stock valued at $93,000 after purchasing an additional 1,341 shares during the period. NumerixS Investment Technologies Inc acquired a new position in Gossamer Bio during the 4th quarter valued at about $150,000. Royal Bank of Canada lifted its position in Gossamer Bio by 39.3% during the 2nd quarter. Royal Bank of Canada now owns 6,967 shares of the company’s stock valued at $154,000 after purchasing an additional 1,967 shares during the period. Finally, Quantitative Systematic Strategies LLC acquired a new position in Gossamer Bio during the 4th quarter valued at about $172,000. Institutional investors own 61.59% of the company’s stock.

Gossamer Bio Company Profile (NASDAQ:GOSS)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.

Read More: Market Perform

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.